APLM logo

APOLLOMICS INC

APLMNASDAQ
🏆 #4462 by market capEarnings Apr 1US Equity
$24.02▼ $3.04 (−12.64%)
Market closed · at close
🔔
Track APLM
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 12.6%
7d▲ 0.0%
14d▲ 0.0%
30d▼ 9.2%
ytd▲ 28.5%
1y▲ 33.4%
🏦Market Cap
$53M
Small Cap
📈Revenue Growth (YoY)
+4192.9%
High Growth
📊Gross Margin
100.0%
High
💵FCF Margin
-122.0%
Thin
⚖️P/S Ratio
5.8x
Fair
Otter Score
80
Good

Trading Snapshot

Day Range
$23.75 – $24.28
52-Week Range
$10.01 – $42.12
Volume
$2.66B
Avg Volume
$1.96B
Shares Outstanding
2.2M
Next Earnings
Nov 6, 2026

Fundamentals Snapshot

Annual Revenue
$9M
Last Q Revenue
$2M
P/E Ratio
-3.0
P/S Ratio
5.8x
EPS (TTM)
$-25.98
Dividend Yield
0.00%
Dilution (1yr)
−61.8%

Why Investors Own APLM

  • ✓High-growth profile — revenue up -9.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 47% gross margin and 27% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

APLM logo

APOLLOMICS INC

APLM
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$9M▲ +4192.9% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
97.0%▼ −3.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$9M▼ −77.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$10M▼ −64.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
421K▼ −61.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$3M▼ −$6M YoY
StockOtter · stockotter.space

About APOLLOMICS INC

Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
80/100

Analyst Ratings

ⓘ
Consensus
Buy
7 analysts
Strong Buy2
Buy4
Hold1
Sell0
Strong Sell0
Ratings as of Dec 2024

Latest News & Updates

🚀
CNBC·2h ago

APOLLOMICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Barron’s·5h ago

Analysts lift APLM price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
MarketWatch·1d ago

APOLLOMICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.